The 3 analysts offering 12-month price forecasts for Vyne Therapeutics Inc have a median target of 4.00, with a high estimate of 5.00 and a low estimate of 1.50. The median estimate represents a +1,639.13% increase from the last price of 0.23.
The current consensus among 3 polled investment analysts is to Buy stock in Vyne Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.18
Reporting Date Mar 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.